FoxWayne Enterprises Acquisition, a blank check company targeting biotechnology and telemedicine in North America, raised $50 million by offering 5 million units at $10. Each unit consists of one share of common stock and one whole warrant, exercisable at...read more
Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018...read more
Hoth Therapeutics, which is developing topical treatments for eczema, raised $7.0 million by offering 1.25 million shares at $5.60, towards the low end of the range of $5.50 to $6.50. At $5.60, the company commands a market value of $57 million. Hoth...read more
Hoth Therapeutics, which is developing topical treatments for eczema, lowered the proposed deal size for its upcoming IPO on Friday. The New York, NY-based company now plans to raise $8 million by offering 1.3 million shares at a price range of $5.50 to...read more
Healthcare SPAC FoxWayne Enterprises Acquisition prices $50 million IPO
FoxWayne Enterprises Acquisition, a blank check company targeting biotechnology and telemedicine in North America, raised $50 million by offering 5 million units at $10. Each unit consists of one share of common stock and one whole warrant, exercisable at...read more
US IPO Weekly Recap: Blue jeans are back as Levi's preps March IPO
Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018...read more
Hoth Therapeutics prices IPO at $5.60, towards the low end of the range
Hoth Therapeutics, which is developing topical treatments for eczema, raised $7.0 million by offering 1.25 million shares at $5.60, towards the low end of the range of $5.50 to $6.50. At $5.60, the company commands a market value of $57 million. Hoth...read more
Eczema biotech Hoth Therapeutics decreases proposed IPO deal size
Hoth Therapeutics, which is developing topical treatments for eczema, lowered the proposed deal size for its upcoming IPO on Friday. The New York, NY-based company now plans to raise $8 million by offering 1.3 million shares at a price range of $5.50 to...read more